<DOC>
	<DOCNO>NCT00211497</DOCNO>
	<brief_summary>This Phase II , randomize , vehicle-controlled , double-blind , multi center study evaluate efficacy safety topically apply MBI 226 1.25 % 2.5 % Acne Solutions anti-acne preparation human subject facial acne vulgaris .</brief_summary>
	<brief_title>Safety Efficacy MBI 226 1.25 % 2.5 % Topical Acne Solutions Treatment Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Males females 12 year old Presence inflammatory noninflammatory lesion Acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc . ) Active facial cyst nodulocystic lesion</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>acne vulgaris</keyword>
	<keyword>acne</keyword>
	<keyword>Propionibacterium acne</keyword>
	<keyword>topical</keyword>
	<keyword>inflammatory</keyword>
	<keyword>non-inflammatory</keyword>
	<keyword>lesion count</keyword>
	<keyword>lesion</keyword>
</DOC>